Revolutionizing the global fight against cancer by developing highly accurate cancer screening blood
Location: United States, New York
Employees: 11-50
Total raised: $11.3M
Founded date: 2013
Investors 2
| Date | Name | Website |
| 10.07.2026 | 1955 Capit... | 1955.capit... |
| - | XLerateHea... | xleratehea... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.08.2022 | Series A | $11.3M | - |
Mentions in press and media 2
| Date | Title | Description |
| 27.08.2026 | Acuamark Diagnostics Announces Two Peer-Reviewed Publications on Sequencing-Free Blood Test for Early Colorectal Cancer | Top models achieved 92% sensitivity at 97% specificity across Stages I–IV colorectal cancer in a validation subset — on a PCR-based assay Early cancer detection is both a biology challenge and a deployment challenge. Unlocking Stage I and I... |
| 20.07.2022 | Acuamark Diagnostics Raises $11.3M in Series A Funding | AcuamarkDx Secures Series A Funding and Welcomes New Member to Board of Directors Acuamark Diagnostics, a NYC-based early cancer detection company, closed an $11.3m Series A funding round. The round was led by the office of Claudio Del Vecc... |